Japanese pharma group Daiichi Sankyo has reached a deal to sell its consumer healthcare division to food and beverage giant ...

The Michael J Fox Foundation for Parkinson's Research (MJFF) has started working with Swiss biotech Biognosys on a project ...

Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that it says brings together computational ...

For too long, MASLD care has relied on a narrow playbook: lifestyle advice, routine monitoring, and waiting for signs of ...

The FDA may have approved Eli Lilly's oral weight-loss drug Foundayo in record time, but it still needs to see more safety ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...

Rare neurological disease has undergone a meaningful shift over the past decade. Advances in human genetics, expanded access ...

On today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Thomas Goetz, former executive editor of ...

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...

For now, the FDA is simply asking trial sponsors to make sure they meet the required reporting standards, but it has also ...

Novo Nordisk has become the latest big pharma group to forge an alliance with AI giant OpenAI, seeking to turbocharge its ...

Revolution Medicines thinks it could transform the treatment of pancreatic cancer – one of the hardest forms to treat – based ...